These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2445 related articles for article (PubMed ID: 8069095)
1. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a. Mayer P; Handgretinger R; Bruchelt G; Schaber B; Rassner G; Fierlbeck G Melanoma Res; 1994 Apr; 4(2):101-6. PubMed ID: 8069095 [TBL] [Abstract][Full Text] [Related]
2. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. Hank JA; Surfus J; Gan J; Chew TL; Hong R; Tans K; Reisfeld R; Seeger RC; Reynolds CP; Bauer M J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):29-37. PubMed ID: 8110728 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro. Kawashima I; Tada N; Fujimori T; Tai T J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721 [TBL] [Abstract][Full Text] [Related]
4. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model. Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118 [TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Honsik CJ; Jung G; Reisfeld RA Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017 [TBL] [Abstract][Full Text] [Related]
6. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Barker E; Mueller BM; Handgretinger R; Herter M; Yu AL; Reisfeld RA Cancer Res; 1991 Jan; 51(1):144-9. PubMed ID: 1988079 [TBL] [Abstract][Full Text] [Related]
7. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368 [TBL] [Abstract][Full Text] [Related]
8. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871. Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758 [TBL] [Abstract][Full Text] [Related]
9. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727 [TBL] [Abstract][Full Text] [Related]
10. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994 [TBL] [Abstract][Full Text] [Related]
11. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Kushner BH; Cheung NK Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202 [TBL] [Abstract][Full Text] [Related]
12. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Munn DH; Cheung NK Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978 [TBL] [Abstract][Full Text] [Related]
14. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. Helfand SC; Hank JA; Gan J; Sondel PM Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851 [TBL] [Abstract][Full Text] [Related]
15. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Kushner BH; Cheung NK Blood; 1989 May; 73(7):1936-41. PubMed ID: 2653466 [TBL] [Abstract][Full Text] [Related]
16. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance. Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024 [TBL] [Abstract][Full Text] [Related]
17. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Chen RL; Reynolds CP; Seeger RC Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607 [TBL] [Abstract][Full Text] [Related]
19. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Cheresh DA; Honsik CJ; Staffileno LK; Jung G; Reisfeld RA Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5155-9. PubMed ID: 3860849 [TBL] [Abstract][Full Text] [Related]
20. Recombinant antibodies against ganglioside expressed on tumor cells. Hanai N; Nakamura K; Shitara K Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]